Home Tags ADC Therapeutics

Tag: ADC Therapeutics

Featured Image: ADC Therapeutics Booth at AACR 2018 Courtesy: © 2017 – 2018. Sunvalley Communication, LLC / Evan Wendt. Used with permission.

Loncastuximab Tesirine Shows Early Promise in Patients with Relapsed/Refractory B-cell Non-Hodgkin...

Loncastuximab tesirine, also known as ADCT-402, an investigational antibody-drug conjugate being developed by ADC Therapeutics, showed signs of clinical activity in patients with relapsed/refractory...
Featured Image: ADC Therapeutics Booth at AACR 2018 Courtesy: © 2017 – 2018. Sunvalley Communication, LLC / Evan Wendt. Used with permission.

Freenome Enters Biomarker Development Collaboration with ADC Therapeutics

Swiss-based ADC Therapeutics, an oncology-drug development company specializes in the development of antibody drug conjugates (ADCs), and Freenome, a biotech company pioneering the a...

SOPHiA Genetics and ADC Therapeutics Partner for Biomarker Discovery in Pivotal...

ADC Therapeutics and SOPHiA GENETICS have entered into a collaboration to identify genomic markers associated with clinical response to loncastuximab tesirine (ADCT-402), an antibody...
Featured Image: View of Lugano old town with mountains in the background, Switzerland. Courtesy: © 2017. Fotolia. Used with permission.

Pyrrolobenzodiazepine-based ADCs Demonstrate Potential in R/R Lymphomas

The International Conference on Malignant Lymphoma (ICML) has, since its first edition in 1981, become one of the must-attend conferences for the scientific community...
Scientist pipetting

ADC Therapeutics Expands Agreement with Synaffix

The Netherlands-based biotechnology company Synaffix, which develops clinical-stage technologies for the development of best-in-class antibody-drug conjugates or ADCs, confirmed that ADC Therapeutics has triggered...

ADC Therapeutics and Adagene Enter into a Discovery Collaboration and License...

ADC Therapeutics, headquartered in Lausanne, Switzerland, and Adagene, a clinical stage biotech company based in Suzhou, China and San Francisco, USA, have entered into...

First Patient Dosed in Phase I Trial with Pyrrolobenzodiazepine-based Antibody-drug conjugate...

The development of proprietary, pyrrolobenzodiazepine-based, antibody-drug conjugates or ADCs targeting AXL, has entered a news phase with the dosing of the first patient in...

ADC Therapeutics Ends ADCT-502 Development Program

Earlier this week Lausanne, Switzerland-based ADC Therapeutics, an oncology drug discovery and development company specializing in the development of proprietary antibody-drug conjugates or ADCs...

Interim Data Shows Favorable Tolerability and Efficacy Results of ADCT-301 in...

Interim results from an ongoing Phase I, open label, dose-escalating study evaluating ADCT-301, being developed by ADC Therapeutics for the treatment of relapsed or refractory...

First Patient with Advanced Solid Tumors with HER2 Expression Dosed in...

A first patient with advanced solid tumors with HER2 Expression was dosed in a phase I clinical trial with ADCT-502. The investigational drug being...